


FIG. 1 Percent body weight change in HBCx-9 PDX model



10 FIG. 2 Anti-tumour activity of AZD5305 in combination with carboplatin in HBCx-9 PDX model




FIG. 3 Anti-tumour activity of AZD5305 in combination with carboplatin in HBCx-9 PDX model (individual animals)






FIG. 4 XRPD diffractogram for AZD5305 – Form A



5


3/5

FIG.5 Percent body weight change in SUM149PT xenograft model




10

FIG.6 Anti-tumour activity of AZD5305 in combination with carboplatin in SUM149PT xenograft model




15

FIG.7 Percent body weight change in HBCx-9 PDX model



10 FIG. 8 Anti-tumour activity of AZD5305 in combination with carboplatin in HBCx-9 model



**Fig. 9 Durability of anti-tumour activity of AZD5305 in combination with carboplatin upon cessation of treatment in HBCx-9 model**

